Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,740Revenue (TTM) $M15.0Net Margin (%)-940.6Altman Z-Score39.3
Enterprise Value $M3,432EPS (TTM) $-1.6Operating Margin %-982.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)-940.6Higher ROA y-yY
Price/Book11.910-y EBITDA Growth Rate %--Quick Ratio10.2Cash flow > EarningsY
Price/Sales2485-y EBITDA Growth Rate %--Current Ratio10.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-37.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M87.1ROIC % (ttm)-963.5Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NBIX is held by these investors:



NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lloyd-Smith MalcolmChief Regulatory Officer 2017-02-07Sell843$43.35-0.97view
BENEVICH ERICChief Commercial Officer 2017-02-07Sell953$43.32-0.9view
Lippoldt DarinChief Legal Officer 2017-02-07Sell953$43.34-0.95view
Grigoriadis Dimitri E.Chief Research Officer 2017-02-06Sell727$43.13-0.46view
Bozigian Haig P.Chief Development Officer 2017-02-06Sell963$43.14-0.49view
Gano KyleChief Business Development Off 2017-02-06Sell727$43.15-0.51view
OBrien Christopher FlintChief Medical Officer 2017-02-06Sell1,206$43.17-0.56view
Coughlin Timothy PCFO 2017-02-06Sell963$43.14-0.49view
GORMAN KEVIN CHARLESCEO 2017-02-06Sell3,010$43.18-0.58view
Bozigian Haig P.Chief Development Officer 2017-02-03Sell1,375$42.570.85view

Quarterly/Annual Reports about NBIX:

News about NBIX:

Articles On GuruFocus.com
AbbVie: Encouraging Results From Elagolix Study Oct 20 2016 
Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive Mar 24 2017
Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3... Mar 21 2017
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events Mar 13 2017
NEUROCRINE BIOSCIENCES INC Financials Feb 18 2017
Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease Feb 16 2017
[2/15] Today's Top 10 Long/Short Estimize Signal Scores Feb 15 2017
Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT Feb 14 2017
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 14 2017
Neurocrine reports 4Q loss Feb 14 2017
Neurocrine reports 4Q loss Feb 14 2017
Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 Feb 14 2017
Q4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close Feb 14 2017
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Feb 10 2017
Neurocrine Inks $145 Million Parkinson's Drug Deal Feb 10 2017
Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone Feb 09 2017
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End... Feb 07 2017
[2/7] Today's Top 10 Long/Short Estimize Signal Scores Feb 07 2017
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US :... Feb 01 2017
Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen Jan 27 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)